Corrigendum to: GFP to BFP Conversion: A versatile assay for the quantification of CRISPR/Cas9-mediated genome editing (Molecular Therapy - Nucleic Acids (2016) 5 (e334) DOI: 10.1038/mtna.2016.48);GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9-mediated Genome Editing

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e334-

  Glaser, Astrid ^a,b   McColl, Bradley ^a   Vadolas, Jim ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLUE FLUORESCENT PROTEIN; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; AMINO ACID; CAS9 PROTEIN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CRISPR ASSOCIATED PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DNA END JOINING REPAIR; DNA REPAIR; ELECTROPORATION; FLOW CYTOMETRY; FLUORESCENCE; GENE EDITING; HOMOLOGY DIRECTED REPAIR; LETTER; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SILENT MUTATION; TARGET CELL; CHROMATOPHORE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; INDEL MUTATION; K-562 CELL LINE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; TRANSFORMED CELL; UBIQUITINATION; WILD TYPE;

EID: 85015187315     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.78     Document Type: Erratum

References (13)

1. 1 Doudna, JA, Charpentier, E, Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
2. 2 Ran, FA, Hsu, PD, Wright, J, Agarwala, V, Scott, DA, Zhang, F, Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8 (2013), 2281–2308.
3. 3 Kim, H, Kim, JS, A guide to genome engineering with programmable nucleases. Nat Rev Genet 15 (2014), 321–334.
4. 4 De Ravin, SS, Reik, A, Liu, PQ, Li, L, Wu, X, Su, L, et al. Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 34 (2016), 424–429.
5. 5 Yu, C, Liu, Y, Ma, T, Liu, K, Xu, S, Zhang, Y, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 (2015), 142–147.
6. 6 Chu, VT, Weber, T, Wefers, B, Wurst, W, Sander, S, Rajewsky, K, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 33 (2015), 543–548.
7. 7 Maruyama, T, Dougan, SK, Truttmann, MC, Bilate, AM, Ingram, JR, Ploegh, HL, Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33 (2015), 538–542.
8. 8 Certo, MT, Ryu, BY, Annis, JE, Garibov, M, Jarjour, J, Rawlings, DJ, et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8 (2011), 671–676.
9. 9 Hendel, A, Kildebeck, EJ, Fine, EJ, Clark, JT, Punjya, N, Sebastiano, V, et al. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep 7 (2014), 293–305.
10. 10 Miyaoka, Y, Chan, AH, Judge, LM, Yoo, J, Huang, M, Nguyen, TD, et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 11 (2014), 291–293.
11. 11 Heim, R, Prasher, DC, Tsien, RY, Wavelength mutations and posttranslational autoxidation of green fluorescent protein. Proc Natl Acad Sci USA 91 (1994), 12501–12504.
12. 12 Howden, SE, Voullaire, L, Wardan, H, Williamson, R, Vadolas, J, Site-specific, Rep-mediated integration of the intact beta-globin locus in the human erythroleukaemic cell line K562. Gene Ther 15 (2008), 1372–1383.
13. 13 Arpino, JA, Reddington, SC, Halliwell, LM, Rizkallah, PJ, Jones, DD, Random single amino acid deletion sampling unveils structural tolerance and the benefits of helical registry shift on GFP folding and structure. Structure 22 (2014), 889–898.